Table 1.
Descriptive categorical data for the whole study population
|
Variable
|
|
n
(%) |
| Etiology of cirrhosis | HCV | 148 (87.6) |
| HBV | 5 (3) | |
| Combined HCV & HBV | 4 (2.4) | |
| Others | 12 (7.1) | |
| Hepatocellular carcinoma | - | 109 (64.5) |
| + | 60 (35.5) | |
| Donors’ gender | Male | 141 (83.4) |
| Female | 28 (16.6) | |
| Recipients’ gender | Male | 150 (88.8) |
| Female | 19 (11.2) | |
| HCV PCR viremia prior to transplantation | Negative | 33 (19.52) |
| Below 200 000 IU | 59 (34.91) | |
| 200000 to 2 million | 69 (40.82) | |
| More than 2 million | 8 (4.73) | |
| Antiviral treatment for HCV prior to transplantation | - | 138 (81.7) |
| + | 31 (18.3) | |
| Arterial complications | - | 155 (91.7) |
| + | 14 (8.3) | |
| Number of anastomosis | 1 Anastomosis | 109 (64.5) |
| 2 Anastomosis | 57 (33.7) | |
| 3 Anastomosis | 3 (1.8) | |
| Number of ducts | 1 Duct | 78 (46.2) |
| 2 Ducts | 78 (46.2) | |
| 3 Ducts | 12 (7.1) | |
| 4 Ducts | 1 (0.6) | |
| Number of stents introduced at surgery | Nil | 7 (4.1) |
| 1 Stent | 71 (42) | |
| 2 Stents | 79 (46.7) | |
| 3 Stents | 11 (6.5) | |
| 4 Stents | 1 (0.6) | |
| Immunosuppressant | Tacrolimus | 118 (69.8) |
| Cyclosporine | 51 (30.2) | |
| Biliary leakage | - | 114 (67.5) |
| + | 55 (32.5) | |
| Need of pigtail catheter for biloma | - | 46 (83.6) |
| + | 9 (16.4) | |
| Biliary infection | - | 72 (42.6) |
| + | 97 (57.4) | |
| Frequency of biliary infection | 1-2 Episodes | 84 (49.7) |
| ≥ 3 Episodes | 13 (7.7) | |
| Biliary stricture | - | 109 (64.5) |
| + | 60 (35.5) | |
| Frequency of biliary stricture | 1-2 Episodes | 43 (25.4) |
| ≥ 3 Episodes | 17 (10.1) | |
| Need for ERCP | - | 109 (64.5) |
| + | 60 (35.5) | |
| Frequency of ERCP | 1-2 ERCP | 42 (24.9) |
| ≥ 3 ERCP | 18 (10.7) | |
| Need for PTC | - | 161 (95.3) |
| + | 8 (4.7) | |
| Frequency of PTC | 1 PTC | 7 (4.1) |
| 2 PTC | 1 (0.6) | |
| Surgical intervention for stricture | - | 168 (99.4) |
| + | 1 (0.6) | |
| HCV PCR during occurrence of stricture | Negative | 15 (25) |
| Below 200 000 IU | 15 (25) | |
| 200000 to 2 million | 19 (31.7) | |
| More than 2 million | 11 (18.3) | |
| HCV antiviral treatment in relation to stricture diagnosis | No treatment | 27 (45) |
| Before stricture | 14 (23.3) | |
| During occurrence of stricture | 13 (21.7) | |
| After stricture | 6 (10) | |
| Admission related to BC | - | 95 (56.2) |
| + | 74 (43.8) | |
| Mortality | - | 141 (83.4) |
| + | 28 (16.6) | |
| Cause of mortality (total number: 28) | Biliary sepsis | 5 (17.9) |
| Graft rejection | 4 (14.3) | |
| Recurrent HCV | 3 (10.7) | |
| Other causes | 16 (57.1) | |
| Chronic rejection | - | 142 (84) |
| + | 27 (16) | |
| Recurrent HCV infection | - | 128 (75.7) |
| + | 41 (24.3) | |
| Resolution of recurrent HCV | - | 4 (9.8) |
| + | 37 (90.2) | |
| Graft failure | - | 149 (88.2) |
| + | 20 (11.8) | |
| Causes of graft failure (total number: 20) | Biliary sepsis | 5 (25) |
| Graft rejection | 6 (30) | |
| Recurrent HCV | 3 (15) | |
| Other causes | 6 (30) | |
| Early biliary infection (total = 97) | - | 6 (6.18) |
| + | 91 (93.81) | |
| Early biliary stricture (total = 60) | - | 45 (75) |
| + | 15 (25) |
Data presented in number (n) and percentage (%). HCV: Hepatitis C virus; HBV: Hepatitis B virus; PCR: Polymerase chain reaction; ERCP: Endoscopic retrograde cholangiopancreatography; PTC: Percutaneous transhepatic cholangiography; BC: Biliary complication.